Virtua Health's Participation in Davos Alzheimer's Collaborative U.S. Fellowship Program

Virtua Health's Participation in Davos Alzheimer's Collaborative U.S. Fellowship Program is sponsored by Davos Alzheimer's Collaborative. This opportunity supports mission-aligned projects and measurable outcomes.

Virtua Selected to Participate in Davos Alzheimer's Collaborative U.S. Fellowship Program Virtua Selected to Participate in Davos Alzheimer's Collaborative U.S. Fellowship Program Virtua Health is one of 10 U.S. health systems selected to participate in the project, part of a pioneering worldwide initiative seeking to cure Alzheimer’s disease and improve brain health.

Virtua Health is among 10 U.S. health systems selected to participate in the Davos Alzheimer’s Collaborative Healthcare System Preparedness U.S. Fellowship Program. The project is led by the Davos Alzheimer’s Collaborative (DAC), a pioneering worldwide initiative seeking to cure Alzheimer’s disease and improve brain health.

DAC’s goal is to end Alzheimer’s Disease by mirroring the success of global efforts against infectious diseases such as HIV/AIDS, COVID-19, and malaria. The project is designed to support health systems in implementing early detection of cognitive impairment and Alzheimer’s disease in primary care settings across the United States.

The 10 participating health systems intentionally represent a diverse cross-section of healthcare delivery models, geographic regions, and patient populations. Virtua Health, the largest health system in southern New Jersey, will play a critical role in refining an early detection workflow in primary care based on scalable, evidence-based training, with technical assistance provided by DAC experts.

Virtua, in collaboration with the New Jersey Institute for Successful Aging (NJISA) at the Rowan-Virtua School of Osteopathic Medicine, will share learnings with the DAC Healthcare System Preparedness team and other health systems through early 2026.

“We are partnering with diverse healthcare systems nationwide to accelerate the adoption of early detection for cognitive impairment using the DAC Healthcare System Preparedness Blueprint.

The program will produce a U.S.-specific early detection Blueprint, offering evidence-based training and tools to enable health systems to implement programs quickly and sustainably, ultimately improving access to cognitive evaluation for millions of Americans,” said Tim MacLeod, Ph. D. , director of DAC Healthcare System Preparedness.

“Virtua recognizes the growing population of individuals 65 and older and is committed to expanding our clinical capacities and developing programs that reflect their distinct needs,” said Jennifer Khelil , DO, MBA, Virtua’s executive vice president and chief clinical officer.

“Virtua’s inclusion in DAC and academic affiliation with Rowan University support our goal of attaining IHI Age-Friendly Health System designation for Virtua’s five hospitals and its 36 primary care practices.

” In July 2025, Virtua Health, in collaboration with the Virtua-Rowan NJISA, will begin an eight-year journey as participants in the Centers for Medicare & Medicaid Innovation (CMMI) Guiding an Improved Dementia Experience (GUIDE) Model, demonstrating its intention to provide dementia-capable interprofessional team-based care for patients and families.

The medical school will offer its expertise in geriatric clinical services, education, and training for healthcare professionals and the healthcare workforce, translational research, related artificial intelligence (AI) applications to support cognitive screening, and longstanding provision of interprofessional, team-based dementia care through its Memory Assessment Program.

“The U.S. Fellowship Program, and the generous grant that supports our participation, will serve as a catalyst for Virtua Medical Group to offer an array of new and expanded dementia-related services for older individuals,” explained Sam Weiner, MD, chief medical officer for VMG and a vice president with Virtua Health.

“Virtua is grateful for this opportunity to participate in this initiative focused on improving early detection and the accurate diagnosis of our many patients living with Alzheimer’s Disease. ”